Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Intervalo de año de publicación
1.
J Cardiovasc Med (Hagerstown) ; 25(2): 158-164, 2024 02 01.
Artículo en Inglés | MEDLINE | ID: mdl-38149702

RESUMEN

AIMS: There is wide variability in the practice of cardiac preservation for heart transplantation. Prior reports suggest that the type of solution may be linked with a reduced incidence of posttransplantation complications. METHODS: Adult (≥18 years old) heart recipients who underwent transplantation between 2015 and 2021 in the United States were examined. Recipients were stratified by solution utilized for their grafts at the time of recovery: University of Wisconsin, histidine-tryptophan-ketoglutarate (HTK), or Celsior solution. The primary endpoint was a composite of 30-day mortality, primary graft dysfunction, or re-transplantation. Risk adjustment was performed for the recipient, donor, and procedural characteristics using regression modeling. RESULTS: Among 16 884 recipients, the group distribution was University of Wisconsin solution 53%, HTK 22%, Celsior solution 15%, and other 10%. The observed incidence of the composite endpoint (University of Wisconsin solution = 3.6%, HTK = 4.0%, Celsior solution = 3.7%, P = 0.301) and 1-year survival (University of Wisconsin solution = 91.7%, HTK = 91.3%, Celsior solution = 91.7%, log-rank P = 0.777) were similar between groups. After adjustment, HTK was associated with a higher risk of the composite endpoint [odds ratio (OR) 1.249, 95% confidence interval (CI) 1.019-1.525, P = 0.030] in reference to University of Wisconsin solution. This association was substantially increased among recipients with ischemic periods of greater than 4 h (OR 1.817, 95% CI 1.188-2.730, P = 0.005). The risks were similar between University of Wisconsin solution and Celsior solution (P = 0.454). CONCLUSION: The use of the histidine-tryptophan-ketoglutarate solution during cold static storage for cardiac preservation is associated with increased rates of early mortality or primary graft dysfunction. Clinician discretion should guide its use, especially when prolonged ischemic times (>4 h) are anticipated.


Asunto(s)
Trasplante de Corazón , Soluciones Preservantes de Órganos , Disfunción Primaria del Injerto , Adulto , Humanos , Adolescente , Preservación de Órganos/efectos adversos , Disfunción Primaria del Injerto/etiología , Disfunción Primaria del Injerto/prevención & control , Soluciones Preservantes de Órganos/efectos adversos , Trasplante de Corazón/efectos adversos , Insulina , Glucosa/efectos adversos
2.
Rev. bras. oftalmol ; 54(11): 805-9, nov. 1995. tab
Artículo en Portugués | LILACS | ID: lil-280015

RESUMEN

Os autores analizaram a influência de pequenas variaçöes do pH na preservaçäo de córneas em Optisol (Chiron Ophthalmics, Irvine, California). Dez pares de córneas humanas foram armazenadas por cinco dias, com Optisol, em pH 7,0 7,2 e 7,5 e depois analisados com lâmpada de fenda, microscópio especular e microscopia eletrônica. Näo foram encontradas diferenças significativas nem na contagem endotelial,nem nas caacterísticasmorfológicas do endotélio corneano nas córneas preservadas nesses pHs


Asunto(s)
Humanos , Adulto , Persona de Mediana Edad , Córnea/efectos de los fármacos , Córnea/fisiología , Medios de Cultivo/análisis , Medios de Cultivo/química , Medios de Cultivo/farmacología , Soluciones Preservantes de Órganos , Soluciones Preservantes de Órganos/efectos adversos , Soluciones Preservantes de Órganos/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA